

Description générale

Imatinib is a BCR-ABL tyrosine kinase inhibitor used in treatment protocols for various leukaemias and solid tumours.

INN	Imatinib
Codes ATC	L01EA01
Type de médicament	Chemical agent
Historique des statuts LME	Ajouté pour la première fois en 2015 (TRS 994) pour Chronic myeloid leukaemia, not elsewhere classified Ajouté en 2015 (TRS 994) pour Gastrointestinal stromal tumour of unspecified gastrointestinal sites Ajouté en 2021 (TRS 1035) pour B lymphoblastic leukaemia or lymphoma with t(9:22) (q34;q11.2); BCR-ABL1
Wikipédia	Imatinib 
DrugBank	Imatinib 

Recommandations

Section Targeted therapies

Oral > Solid: 100 mg; 400 mg

Indications

Chronic myeloid leukaemia, not elsewhere classified

Gastrointestinal stromal tumour of unspecified gastrointestinal sites

B lymphoblastic leukaemia or lymphoma with t(9:22) (q34;q11.2); BCR-ABL1

